Innovacell Inc is engaged in the development, manufacturing, and sale of regenerative medicine products for the treatment of conditions including fecal and urinary incontinence. Innovacell (TKS: 504A) is based in Tokyo, Japan. It is now publicly traded; this page covers its private-market history, where its last recorded valuation was $364 million (Feb 2026). It has raised $193 million.
Last price · $/share
—
Implied valuation
$364.2M
Total raised
$193.4M
Last round
—
Cap table — not yet on record
Innovacell (TKS: 504A)'s share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Innovacell (TKS: 504A) with a free account
·The complete investor list: 26 names
·Watch Innovacell (TKS: 504A): the Monday email on marks, rounds and moves
